Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.

Sustained release nanoparticulate formulations of Rivastigmine tartrate (RT) were prepared, optimized (using factorial design) and characterized using the biodegradable polymers, PLGA and PBCA as carriers. The pharmacodynamic performances of the nanoparticles (NPs) were evaluated for brain targeting and memory improvement in scopolamine-induced amnesic mice using Morris Water Maze Test. PLGA NPs were prepared by nanoprecipitation technique, while PBCA NPs were prepared by emulsion polymerization technique. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using factorial design. PLGA NPs showed PS of 135.6±4.2nm and PDE of 74.46±0.76 %, whereas PBCA NPS showed PS of 146.8±2.6nm and PDE of 57.32±0.91%. FTIR and GPC characterization confirmed complete polymerization of n-butyl cyanoacrylate (nBCA) monomer into PBCA. DSC thermograms indicated that RT was dispersed as amorphous state in both PLGA and PBCA NPs. TEM studies indicated that the NPs were spherical. In vitro studies showed 30.86±2.07% and 43.59±3.80% release from PLGA and PBCA NPs in 72h, respectively. Pharmacodynamic study demonstrated faster regain of memory loss in amnesic mice with both PLGA and PBCA NPs when compared to RT solution. This indicates rapid and higher extent of transport of RT into the mice brain and thus shows the suitability of both NPs as potential carriers for providing sustained brain delivery of RT.

[1]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[2]  Indu Bala,et al.  PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.

[3]  J. Gallo,et al.  Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors , 2005, Journal of Neuro-Oncology.

[4]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[5]  N. Behan,et al.  Preparation of Poly(butyl cyanoacrylate) Nanoparticles by Aqueous Dispersion Polymerisation in the Presence of Insulin , 2001 .

[6]  William G. Cochran,et al.  Experimental designs, 2nd ed. , 1957 .

[7]  Anderson,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.

[8]  The Burden of Dementia: A Medical and Research Perspective , 1999, Theoretical medicine and bioethics.

[9]  K. Sawant,et al.  Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery , 2009, Journal of microencapsulation.

[10]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[11]  Michael Montagne,et al.  Pharmaceutical Statistics: Practical and Clinical Applications , 1985 .

[12]  K. Sawant,et al.  Buccal Bioadhesive Delivery System of 5-Fluorouracil: Optimization and Characterization , 2008 .

[13]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Behan,et al.  Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. , 2001, Biomaterials.

[15]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[16]  A. Misra,et al.  Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting , 2008, Alzheimer disease and associated disorders.

[17]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  Haixiong Ge,et al.  DOXORUBICIN-LOADED POLY(BUTYLCYANOACRYLATE) NANOPARTICLES PRODUCED BY EMULSIFIER-FREE EMULSION POLYMERIZATION , 2000 .

[19]  Yong Hu,et al.  Preparation, characterization, and drug release behaviors of drug nimodipine‐loaded poly(ε‐caprolactone)‐poly(ethylene oxide)‐poly(ε‐caprolactone) amphiphilic triblock copolymer micelles , 2002 .

[20]  M. Wirth,et al.  Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics. , 1999, Journal of microencapsulation.

[21]  C. Geula,et al.  Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles , 2005, Brain Research.

[22]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[23]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[24]  M. Srinath,et al.  Development of three layered buccal compact containing metoprolol tartrate by statistical optimization technique. , 2005, International journal of pharmaceutics.

[25]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[26]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[27]  A. Dhake,et al.  Formulation and evaluation of sustained release microspheres of poly-lactide-co-glycolide containing tamoxifen citrate , 2005, Journal of microencapsulation.

[28]  Yangde Zhang,et al.  Cationic Polybutyl Cyanoacrylate Nanoparticles for DNA Delivery , 2009, Journal of biomedicine & biotechnology.

[29]  M Dunne,et al.  Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. , 2000, Biomaterials.

[30]  B. Sabel,et al.  Nanoparticle technology for delivery of drugs across the blood-brain barrier. , 1998, Journal of pharmaceutical sciences.

[31]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[32]  A. Zimmer,et al.  Studies on the transport pathway of PBCA nanoparticles in ocular tissues. , 1991, Journal of microencapsulation.

[33]  Y. Tsai,et al.  Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. , 2005, International journal of pharmaceutics.

[34]  S. Davis,et al.  PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Jayanth Panyam,et al.  Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Akira Tsuji,et al.  Drug delivery through the blood-brain barrier , 1996 .

[37]  A. Ludwig,et al.  Preparation factors affecting the properties of polylactide nanoparticles: a factorial design study. , 2001, Die Pharmazie.

[38]  T. Lecompte,et al.  In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits , 2002, Circulation.

[39]  O. Corrigan,et al.  Quantifying drug release from PLGA nanoparticulates. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[41]  M. Morishita,et al.  Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.

[42]  E. Allémann,et al.  Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[43]  R. Murthy,et al.  Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. , 2004, Acta pharmaceutica.

[44]  N. Bodor,et al.  A strategy for delivering peptides into the central nervous system by sequential metabolism. , 1992, Science.

[45]  C. Zimmer,et al.  Optimization of polyalkylcyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics , 1992 .

[46]  Alexander V Kabanov,et al.  Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. , 2002, Advanced drug delivery reviews.

[47]  Jiangning Chen,et al.  Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. , 2003, Biomaterials.

[48]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[49]  P. Ellaiah,et al.  Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[50]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[51]  Naveen Ahuja,et al.  Development of Controlled-Release Buccoadhesive Hydrophilic Matrices of Diltiazem Hydrochloride: Optimization of Bioadhesion, Dissolution, and Diffusion Parameters , 2002, Drug development and industrial pharmacy.

[52]  S. Feng,et al.  Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[53]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[54]  R. M. Joyce.  Experiment optimization in chemistry and chemical engineering, S. Akhnazarova and V. Kafarov, Mir Publishers, Moscow and Chicago, 1982, 312 pp. Price: $9.95. , 1984 .

[55]  J. S. Hunter,et al.  Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building. , 1979 .

[56]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001 .

[57]  Chi-Yu Huang,et al.  Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: synthesis, characterization and in vitro degradation. , 2006, International journal of pharmaceutics.

[58]  V. Cotter.  The burden of dementia. , 2007, The American journal of managed care.

[59]  J. Kreuter,et al.  Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[60]  G. Dellamora-Ortiz,et al.  A new sunscreen of the cinnamate class: synthesis and enzymatic hydrolysis evaluation of glyceryl esters of p-methoxycinnamic acid. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.